Corvus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Corvus Pharmaceuticals, Inc. on March 19, 2021, covering events occurring on March 18, 2021. The Company is a Delaware corporation with its principal executive offices in Burlingame, California, and its common stock trades on the Nasdaq Global Market under the symbol CRVS.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding corporate governance changes rather than a periodic financial report.
Material Changes
The primary material event reported is the resignation of Steve Krognes from the Board of Directors, effective on or around March 18, 2021. Mr. Krognes also indicated he will not stand for reelection at the upcoming annual meeting of shareholders scheduled for June 15, 2021. The Company explicitly states that this resignation is not the result of any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding Mr. Krognes' resignation. It references the risks and uncertainties described in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company does not plan to publicly update or revise the forward-looking statements contained in this report.
Key Facts for Investor Verification
- Steve Krognes is resigning from the Board of Directors effective March 18, 2021.
- Mr. Krognes will not seek reelection at the annual meeting scheduled for June 15, 2021.
- The resignation is not due to any disagreement with the Company.
- Investors should review the most recent Form 10-K and Form 10-Q for comprehensive risk factors and financial data not included in this 8-K.